Join

Compare · NVO vs PHAR

NVO vs PHAR

Side-by-side comparison of Novo Nordisk A/S (NVO) and Pharming Group N.V. ADS each representing 10 (PHAR): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both NVO and PHAR operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • NVO is the larger of the two at $173.66B, about 255.3x PHAR ($680.1M).
  • Over the past year, NVO is down 30.4% and PHAR is down 32.8% - NVO leads by 2.4 points.
  • PHAR has been more active in the news (4 items in the past 4 weeks vs 3 for NVO).
  • NVO has more recent analyst coverage (25 ratings vs 2 for PHAR).
PerformanceNVO-30.36%PHAR-32.79%
2025-10-20+0.00%2026-10-16
MetricNVOPHAR
Company
Novo Nordisk A/S
Pharming Group N.V. ADS each representing 10
Price
-
-
Market cap
$173.66B
$680.1M
1M return
-10.14%
-12.57%
1Y return
-30.36%
-32.79%
Sector
Health Care
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NYSE
NASDAQ
IPO
News (4w)
3
4
Recent ratings
25
2
NVO

Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

PHAR

Pharming Group N.V. ADS each representing 10

Pharming Group N.V., a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre- eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

Latest NVO

Latest PHAR